2020年1—2月美国、欧盟和日本新批准药物概述

详细信息

An Overview of New Drugs Approved in the US, EU and Japan in January and February 2020

摘要: 2020年1—2月，美国、欧盟和日本共批准47个新药，包括新分子实体、新有效成分、新生物制品、新增适应证及新剂型药物。对全球首次获得批准的新分子实体、新有效成分、新生物制品进行分析，重点介绍这些药物的临床研究结果和研发历史进程。
- 新药批准 /
- 临床试验 /
- 新分子实体 /
- 新生物制品
Abstract: In January and February 2020, US Food and Drug Administration (FDA), European Commission, and Ministry of Health, Labour and Welfare (MHLW) of Japan had totally approved 47 new drugs, including new molecular entities, new active ingredient, new biologics and new line extensions (new indications and new formulations). In this article, new molecular entities, new active ingredients and new biologics receiving their first global approval were analyzed with emphasis on the outcomes of clinical trials and development histories.
- drug approval /
- clinical trial /
- new molecular entity /
- new biologics

[2]	Gebreyohannes Y K, Wozniak A, Zhai M E, et al. Robust activity of avapritinib, potent and highly selective inhibitor of mutated KIT, in patient-derived xenograft models of gastrointestinal stromal tumors[J]. Clin Cancer Res, 2019, 25(2):609-618.
[3]	Epizyme. Epizyme announces U.S. FDA accelerated approval of TAZVERIK^TM(tazemetostat) for the treatment of patients with epithelioid sarcoma[EB/OL].(2020-01-23)[2020-03-01]. https://epizyme.gcs-web.com/news-releases/news-release-details/epizyme-announces-us-fda-accelerated-approval-tazveriktm.
[4]	Makita S, Tobinai K. Targeting EZH2 with tazemetostat[J]. Lancet Oncol, 2018, 19(5):586-587.
[5]	Horizon Therapeutics. FDA approves TEPEZZA (TM)(teprotumumab-trbw) for the treatment of thyroid eye disease (TED)[EB/OL].(2020-01-21)[2020-02-27]. https://ir.horizontherapeutics.com/news-releases/news-release-details/fdaapproves-tepezzatm-teprotumumab-trbw-treatment-thyroid-eye.
[6]	Douglas R S, Kahaly G J, Patel A, et al. Teprotumumab for the treatment of active thyroid eye disease[J]. N Engl J Med, 2020, 382(4):341-352.